| Covid-19 | Apr 13, 2020

Use of Unregistered Off-Site Location in MAT

The DEA has released guidance providing flexibility in the delivery of controlled substances to ensure necessary patient therapies remain accessible. DEA is temporarily allowing Opioid Treatment Programs to repeatedly use the same off-site location to deliver take-home methadone doses to their patients without separately registering that location with the DEA.